Logo image of BIOC

BIOCEPT INC (BIOC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BIOC - US09072V6002 - Common Stock

0.4349 USD
-0.07 (-13.05%)
Last: 10/24/2023, 8:22:08 PM
0.39 USD
-0.04 (-10.32%)
After Hours: 10/24/2023, 8:22:08 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BIOC. BIOC was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of BIOC have multiple concerns. BIOC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BIOC has reported negative net income.
  • BIOC had a negative operating cash flow in the past year.
BIOC Yearly Net Income VS EBIT VS OCF VS FCFBIOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of BIOC (-239.73%) is worse than 94.21% of its industry peers.
  • BIOC's Return On Equity of -18271.38% is on the low side compared to the rest of the industry. BIOC is outperformed by 87.58% of its industry peers.
Industry RankSector Rank
ROA -239.73%
ROE -18271.38%
ROIC N/A
ROA(3y)-48.71%
ROA(5y)-115.34%
ROE(3y)-148.29%
ROE(5y)-299.94%
ROIC(3y)N/A
ROIC(5y)N/A
BIOC Yearly ROA, ROE, ROICBIOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BIOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOC Yearly Profit, Operating, Gross MarginsBIOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

  • BIOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BIOC has been increased compared to 1 year ago.
  • BIOC has a worse debt/assets ratio than last year.
BIOC Yearly Shares OutstandingBIOC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
BIOC Yearly Total Debt VS Total AssetsBIOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -26.33, we must say that BIOC is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BIOC (-26.33) is worse than 92.05% of its industry peers.
  • A Debt/Equity ratio of 4.70 is on the high side and indicates that BIOC has dependencies on debt financing.
  • The Debt to Equity ratio of BIOC (4.70) is worse than 86.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.7
Debt/FCF N/A
Altman-Z -26.33
ROIC/WACCN/A
WACC12.08%
BIOC Yearly LT Debt VS Equity VS FCFBIOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

  • BIOC has a Current Ratio of 1.81. This is a normal value and indicates that BIOC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.81, BIOC is doing worse than 82.78% of the companies in the same industry.
  • A Quick Ratio of 1.70 indicates that BIOC should not have too much problems paying its short term obligations.
  • BIOC has a Quick ratio of 1.70. This is amonst the worse of the industry: BIOC underperforms 81.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.7
BIOC Yearly Current Assets VS Current LiabilitesBIOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for BIOC have decreased strongly by -42970.00% in the last year.
  • Looking at the last year, BIOC shows a very negative growth in Revenue. The Revenue has decreased by -54.64% in the last year.
  • Measured over the past years, BIOC shows a very strong growth in Revenue. The Revenue has been growing by 38.52% on average per year.
EPS 1Y (TTM)-42970%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.42%
Revenue 1Y (TTM)-54.64%
Revenue growth 3Y67.22%
Revenue growth 5Y38.52%
Sales Q2Q%-94.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.57% on average over the next years. This is a very strong growth
  • The Revenue is expected to decrease by -18.32% on average over the next years. This is quite bad
EPS Next Y86.86%
EPS Next 2Y40.26%
EPS Next 3Y25.57%
EPS Next 5YN/A
Revenue Next Year-93.72%
Revenue Next 2Y-59.48%
Revenue Next 3Y-18.32%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BIOC Yearly Revenue VS EstimatesBIOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BIOC Yearly EPS VS EstimatesBIOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BIOC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOC Price Earnings VS Forward Price EarningsBIOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOC Per share dataBIOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30 -40

4.3 Compensation for Growth

  • BIOC's earnings are expected to grow with 25.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.26%
EPS Next 3Y25.57%

More info and screens

0

5. Dividend

5.1 Amount

  • BIOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCEPT INC

NASDAQ:BIOC (10/24/2023, 8:22:08 PM)

After market: 0.39 -0.04 (-10.32%)

0.4349

-0.07 (-13.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-20
Inst Owners0.43%
Inst Owner Change0%
Ins Owners153.09%
Ins Owner Change0%
Market Cap1.05M
Revenue(TTM)28.13M
Net Income(TTM)-52.99M
Analysts43.33
Price Target4.08 (838.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)83.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-63.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 3.61
P/tB 3.61
EV/EBITDA N/A
EPS(TTM)-43.07
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-7.59
FCFYN/A
OCF(TTM)-7.31
OCFYN/A
SpS11.68
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -239.73%
ROE -18271.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.71%
ROA(5y)-115.34%
ROE(3y)-148.29%
ROE(5y)-299.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.27
Health
Industry RankSector Rank
Debt/Equity 4.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.18%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.7
Altman-Z -26.33
F-Score2
WACC12.08%
ROIC/WACCN/A
Cap/Depr(3y)77.11%
Cap/Depr(5y)65.93%
Cap/Sales(3y)2.95%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42970%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.42%
EPS Next Y86.86%
EPS Next 2Y40.26%
EPS Next 3Y25.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3Y67.22%
Revenue growth 5Y38.52%
Sales Q2Q%-94.45%
Revenue Next Year-93.72%
Revenue Next 2Y-59.48%
Revenue Next 3Y-18.32%
Revenue Next 5YN/A
EBIT growth 1Y-354.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-174%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-251.34%
OCF growth 3YN/A
OCF growth 5YN/A

BIOCEPT INC / BIOC FAQ

What is the fundamental rating for BIOC stock?

ChartMill assigns a fundamental rating of 1 / 10 to BIOC.


What is the valuation status for BIOC stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOCEPT INC (BIOC). This can be considered as Overvalued.


How profitable is BIOCEPT INC (BIOC) stock?

BIOCEPT INC (BIOC) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIOCEPT INC (BIOC) stock?

The Earnings per Share (EPS) of BIOCEPT INC (BIOC) is expected to grow by 86.86% in the next year.